Nephrogenic Systemic Fibrosis - 11/08/11
, Phillip H. Kuo, MD, PhD c, dAbstract |
There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.
Le texte complet de cet article est disponible en PDF.Keywords : Gadolinium, Nephrogenic systemic fibrosis, Gadolinium-based contrast agent, MR imaging, MR contrast agents, Gadolinium chelates
Plan
| J.C.W. has received research support and has served as a consultant and speaker for GE Healthcare and Bayer Healthcare Pharmaceuticals. |
Vol 17 - N° 1
P. 159-167 - février 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
